<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002450</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>38</s160></s100><s200><s210>1</s210><s211>152</s211><s212>PRT</s212><s213>Orthopoxvirus sp.</s213></s200><s400> 1His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn Gly Ser Asp Thr1               5                   10                  15His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln Ile Ile Thr Phe            20                  25                  30Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met Ile Gly Asp Glu        35                  40                  45Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu Phe Phe Ser Leu    50                  55                  60Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp Leu Thr Tyr Phe65                  70                  75                  80Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe Asp Gln Phe Tyr                85                  90                  95Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln Glu Ala Thr Asn            100                 105                 110Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu Lys Lys Trp Phe        115                 120                 125Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu Val Arg Lys Met    130                 135                 140Glu Asp Ser Lys Arg Asn Thr Gly145                 150</s400><s200><s210>2</s210><s211>150</s211><s212>PRT</s212><s213>Orthopoxvirus sp.</s213></s200><s400> 2Gly His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn Gly Ser Asp1               5                   10                  15Thr His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln Ile Ile Thr            20                  25                  30Phe Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met Ile Gly Asp        35                  40                  45Glu Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu Phe Phe Ser    50                  55                  60Leu Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp Leu Thr Tyr65                  70                  75                  80Phe Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe Asp Gln Phe                85                  90                  95Tyr Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln Glu Ala Thr            100                 105                 110Asn Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu Lys Lys Trp        115                 120                 125Phe Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu Val Arg Lys    130                 135                 140Met Glu Asp Ser Lys Arg145                 150</s400><s200><s210>3</s210><s211>150</s211><s212>PRT</s212><s213>Orthopoxvirus sp.</s213></s200><s400> 3His Lys Leu Val His Tyr Phe Asn Leu Lys Ile Asn Gly Ser Asp Ile1               5                   10                  15Thr Asn Thr Ala Asp Ile Leu Leu Asp Asn Tyr Pro Ile Met Thr Phe            20                  25                  30Asp Gly Lys Asp Ile Tyr Pro Ser Ile Ala Phe Met Val Gly Asn Lys        35                  40                  45Leu Phe Leu Asp Leu Tyr Lys Asn Ile Phe Val Glu Phe Phe Arg Leu    50                  55                  60Phe Arg Val Ser Val Ser Ser Gln Tyr Glu Glu Leu Glu Tyr Tyr Tyr65                  70                  75                  80Ser Cys Asp Tyr Thr Asn Asn Arg Pro Thr Ile Lys Gln His Tyr Phe                85                  90                  95Tyr Asn Gly Glu Glu Tyr Thr Glu Ile Asp Arg Ser Lys Lys Ala Thr            100                 105                 110Asn Lys Asn Ser Trp Leu Ile Thr Ser Gly Phe Arg Leu Gln Lys Trp        115                 120                 125Phe Asp Ser Glu Asp Cys Ile Ile Tyr Leu Arg Ser Leu Val Arg Arg    130                 135                 140Met Glu Asp Ser Asn Lys145                 150</s400><s200><s210>4</s210><s211>108</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 4Gln Pro Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Glu1               5                   10                  15Thr Ala Arg Ile Pro Cys Gly Gly Asp Asp Ile Glu Thr Lys Ser Val            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr        35                  40                  45Asp Asp Asp Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Phe Gly Ser    50                  55                  60Asn Ser Gly Asn Thr Ala Thr Leu Ser Ile Ser Arg Val Glu Ala Gly65                  70                  75                  80Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asp Asn Asn Asp Glu                85                  90                  95Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu            100                 105</s400><s200><s210>5</s210><s211>118</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 5Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Lys Asp Arg Phe Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Leu Val Thr Val Ser Ser        115</s400><s200><s210>6</s210><s211>110</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 6Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1               5                   10                  15Ser Ile Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn            20                  25                  30Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu        35                  40                  45Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser    50                  55                  60Gly Ser Lys Ser Gly Thr Ser Ala Phe Leu Ala Ile Ser Gly Leu Gln65                  70                  75                  80Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu                85                  90                  95Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu            100                 105                 110</s400><s200><s210>7</s210><s211>121</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 7Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Lys Asp Arg Gly Leu Gly Asp Gly Thr Tyr Phe Asp Tyr Trp Gly            100                 105                 110Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120</s400><s200><s210>8</s210><s211>241</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 8Gln Pro Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Glu1               5                   10                  15Thr Ala Arg Ile Pro Cys Gly Gly Asp Asp Ile Glu Thr Lys Ser Val            20                  25                  30His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr        35                  40                  45Asp Asp Asp Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Phe Gly Ser    50                  55                  60Asn Ser Gly Asn Thr Ala Thr Leu Ser Ile Ser Arg Val Glu Ala Gly65                  70                  75                  80Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asp Asn Asn Asp Glu                85                  90                  95Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly Gly Gly Gly            100                 105                 110Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val        115                 120                 125Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser    130                 135                 140Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val145                 150                 155                 160Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Phe Ile Arg Tyr                165                 170                 175Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr            180                 185                 190Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser        195                 200                 205Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Phe    210                 215                 220Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser225                 230                 235                 240Ser</s400><s200><s210>9</s210><s211>241</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 9Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Lys Asp Arg Phe Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        115                 120                 125Gly Gly Gly Gly Ser Gln Pro Val Leu Thr Gln Pro Ser Ser Val Ser    130                 135                 140Val Ala Pro Gly Glu Thr Ala Arg Ile Pro Cys Gly Gly Asp Asp Ile145                 150                 155                 160Glu Thr Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro                165                 170                 175Val Leu Val Ile Tyr Asp Asp Asp Asp Arg Pro Ser Gly Ile Pro Glu            180                 185                 190Arg Phe Phe Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Ser Ile Ser        195                 200                 205Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp    210                 215                 220Asp Asn Asn Asp Glu Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val225                 230                 235                 240Leu</s400><s200><s210>10</s210><s211>246</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 10Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln1               5                   10                  15Ser Ile Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn            20                  25                  30Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu        35                  40                  45Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser    50                  55                  60Gly Ser Lys Ser Gly Thr Ser Ala Phe Leu Ala Ile Ser Gly Leu Gln65                  70                  75                  80Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu                85                  90                  95Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly            100                 105                 110Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln        115                 120                 125Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg    130                 135                 140Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His145                 150                 155                 160Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Phe Ile                165                 170                 175Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg            180                 185                 190Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met        195                 200                 205Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp    210                 215                 220Arg Gly Leu Gly Asp Gly Thr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr225                 230                 235                 240Thr Val Thr Val Ser Ser                245</s400><s200><s210>11</s210><s211>246</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 11Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Phe Ile Arg Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Lys Asp Arg Gly Leu Gly Asp Gly Thr Tyr Phe Asp Tyr Trp Gly            100                 105                 110Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly        115                 120                 125Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala    130                 135                 140Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Ser Gly145                 150                 155                 160Ser Ser Ser Asn Ile Gly Asn Asn Ala Val Asn Trp Tyr Gln Gln Leu                165                 170                 175Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Asp Asp Leu Leu Pro            180                 185                 190Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala        195                 200                 205Phe Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr    210                 215                 220Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly225                 230                 235                 240Thr Lys Leu Thr Val Leu                245</s400><s200><s210>12</s210><s211>111</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 12Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala            100                 105                 110</s400><s200><s210>13</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 13Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln1               5                   10                  15Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr            20                  25                  30Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu        35                  40                  45Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr    50                  55                  60Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe65                  70                  75                  80Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala                85                  90                  95Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ala        115</s400><s200><s210>14</s210><s211>245</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 14Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala                245</s400><s200><s210>15</s210><s211>412</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 15Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly                245                 250                 255Gly Gly Gly Ser His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn            260                 265                 270Gly Ser Asp Thr His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln        275                 280                 285Ile Ile Thr Phe Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met    290                 295                 300Ile Gly Asp Glu Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu305                 310                 315                 320Phe Phe Ser Leu Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp                325                 330                 335Leu Thr Tyr Phe Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe            340                 345                 350Asp Gln Phe Tyr Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln        355                 360                 365Glu Ala Thr Asn Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu    370                 375                 380Lys Lys Trp Phe Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu385                 390                 395                 400Val Arg Lys Met Glu Asp Ser Lys Arg Asn Thr Gly                405                 410</s400><s200><s210>16</s210><s211>501</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 16Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala Gly Gly Gly Gly Ser Asp Ile Lys Leu Gln Gln                245                 250                 255Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys            260                 265                 270Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys        275                 280                 285Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser    290                 295                 300Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu305                 310                 315                 320Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu                325                 330                 335Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp            340                 345                 350His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser        355                 360                 365Ser Val Glu Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly    370                 375                 380Gly Val Asp Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile Met Ser Ala385                 390                 395                 400Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val                405                 410                 415Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg            420                 425                 430Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe        435                 440                 445Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met    450                 455                 460Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn465                 470                 475                 480Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys His His His                485                 490                 495His His His His His            500</s400><s200><s210>17</s210><s211>243</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 17Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala1               5                   10                  15Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr            20                  25                  30Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile        35                  40                  45Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe    50                  55                  60Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr65                  70                  75                  80Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly            100                 105                 110Thr Thr Leu Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly        115                 120                 125Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Leu Thr Gln Ser    130                 135                 140Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys145                 150                 155                 160Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser                165                 170                 175Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser            180                 185                 190Gly Val Pro Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser        195                 200                 205Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys    210                 215                 220Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu225                 230                 235                 240Glu Leu Lys</s400><s200><s210>18</s210><s211>420</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 18Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly                245                 250                 255Gly Gly Gly Ser His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn            260                 265                 270Gly Ser Asp Thr His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln        275                 280                 285Ile Ile Thr Phe Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met    290                 295                 300Ile Gly Asp Glu Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu305                 310                 315                 320Phe Phe Ser Leu Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp                325                 330                 335Leu Thr Tyr Phe Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe            340                 345                 350Asp Gln Phe Tyr Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln        355                 360                 365Glu Ala Thr Asn Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu    370                 375                 380Lys Lys Trp Phe Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu385                 390                 395                 400Val Arg Lys Met Glu Asp Ser Lys Arg Asn Thr Gly His His His His                405                 410                 415His His His His            420</s400><s200><s210>19</s210><s211>504</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 19Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gln Val Gln Leu Val Glu                245                 250                 255Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys            260                 265                 270Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg        275                 280                 285Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Phe Ile Arg Tyr Asp    290                 295                 300Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile305                 310                 315                 320Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu                325                 330                 335Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Gly Leu            340                 345                 350Gly Asp Gly Thr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr        355                 360                 365Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly    370                 375                 380Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro385                 390                 395                 400Gly Gln Ser Ile Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly                405                 410                 415Asn Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys            420                 425                 430Leu Leu Ile Tyr Tyr Asp Asp Leu Leu Pro Ser Gly Val Ser Asp Arg        435                 440                 445Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Phe Leu Ala Ile Ser Gly    450                 455                 460Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp465                 470                 475                 480Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu                485                 490                 495His His His His His His His His            500</s400><s200><s210>20</s210><s211>499</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 20Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu                245                 250                 255Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys            260                 265                 270Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg        275                 280                 285Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Phe Ile Arg Tyr Asp    290                 295                 300Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile305                 310                 315                 320Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu                325                 330                 335Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Phe Gly            340                 345                 350Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser        355                 360                 365Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln    370                 375                 380Pro Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Glu Thr385                 390                 395                 400Ala Arg Ile Pro Cys Gly Gly Asp Asp Ile Glu Thr Lys Ser Val His                405                 410                 415Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Asp            420                 425                 430Asp Asp Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Phe Gly Ser Asn        435                 440                 445Ser Gly Asn Thr Ala Thr Leu Ser Ile Ser Arg Val Glu Ala Gly Asp    450                 455                 460Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asp Asn Asn Asp Glu Trp465                 470                 475                 480Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu His His His His His                485                 490                 495His His His</s400><s200><s210>21</s210><s211>232</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 21Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>22</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 22Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>23</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 23Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Thr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>24</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 24Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Ala Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>25</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 25Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Thr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>26</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 26Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>27</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 27Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val            180                 185                 190Ser Phe Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>28</s210><s211>234</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 28Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Trp Val        35                  40                  45Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp    50                  55                  60Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr65                  70                  75                  80Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp                85                  90                  95Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu            100                 105                 110Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Phe        115                 120                 125Arg Pro Glu Val His Leu Leu Pro Pro Ser Arg Glu Glu Met Thr Lys    130                 135                 140Asn Gln Val Ser Leu Thr Cys Leu Ala Arg Gly Phe Tyr Pro Lys Asp145                 150                 155                 160Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys                165                 170                 175Thr Thr Pro Ser Arg Gln Glu Pro Ser Gln Gly Thr Thr Thr Phe Ala            180                 185                 190Val Thr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn        195                 200                 205Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr    210                 215                 220Gln Lys Thr Ile Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>29</s210><s211>235</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 29Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Pro Ser Glu Glu Leu Ala    130                 135                 140Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro145                 150                 155                 160Ser Asp Ile Ala Val Glu Trp Leu Gln Gly Ser Gln Glu Leu Pro Arg                165                 170                 175Glu Lys Tyr Leu Thr Trp Ala Pro Val Leu Asp Ser Asp Gly Ser Phe            180                 185                 190Phe Leu Tyr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp Lys Lys Gly        195                 200                 205Asp Thr Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr    210                 215                 220Thr Gln Lys Ser Leu Asp Arg Ser Pro Gly Lys225                 230                 235</s400><s200><s210>30</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 30Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Ser Pro Pro Ser Arg Asp Glu Leu Thr    130                 135                 140Lys Asn Gln Val Ser Leu Arg Cys His Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Thr Lys Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>31</s210><s211>399</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 31His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn Gly Ser Asp Thr1               5                   10                  15His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln Ile Ile Thr Phe            20                  25                  30Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met Ile Gly Asp Glu        35                  40                  45Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu Phe Phe Ser Leu    50                  55                  60Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp Leu Thr Tyr Phe65                  70                  75                  80Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe Asp Gln Phe Tyr                85                  90                  95Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln Glu Ala Thr Asn            100                 105                 110Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu Lys Lys Trp Phe        115                 120                 125Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu Val Arg Lys Met    130                 135                 140Glu Asp Ser Lys Arg Asn Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly145                 150                 155                 160Gly Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Cys Asp Lys Thr His                165                 170                 175Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            180                 185                 190Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        195                 200                 205Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    210                 215                 220Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys225                 230                 235                 240Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                245                 250                 255Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            260                 265                 270Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        275                 280                 285Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    290                 295                 300Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Tyr Cys Leu305                 310                 315                 320Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                325                 330                 335Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            340                 345                 350Asp Gly Ser Phe Ala Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        355                 360                 365Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    370                 375                 380His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys385                 390                 395</s400><s200><s210>32</s210><s211>492</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 32Asp Ile Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly1               5                   10                  15Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn            20                  25                  30Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Tyr Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser65                  70                  75                  80Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr                85                  90                  95Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly            100                 105                 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val        115                 120                 125Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu    130                 135                 140Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val145                 150                 155                 160His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val                165                 170                 175Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg            180                 185                 190Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met        195                 200                 205Asn Ser Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala    210                 215                 220Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu225                 230                 235                 240Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly                245                 250                 255Gly Gly Gly Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro            260                 265                 270Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe        275                 280                 285Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val    290                 295                 300Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe305                 310                 315                 320Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro                325                 330                 335Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr            340                 345                 350Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val        355                 360                 365Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala    370                 375                 380Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg385                 390                 395                 400Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly                405                 410                 415Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro            420                 425                 430Glu Asn Asn Tyr Lys Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser        435                 440                 445Phe Phe Leu Thr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln    450                 455                 460Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His465                 470                 475                 480Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys                485                 490</s400><s200><s210>33</s210><s211>659</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 33His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn Gly Ser Asp Thr1               5                   10                  15His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln Ile Ile Thr Phe            20                  25                  30Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met Ile Gly Asp Glu        35                  40                  45Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu Phe Phe Ser Leu    50                  55                  60Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp Leu Thr Tyr Phe65                  70                  75                  80Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe Asp Gln Phe Tyr                85                  90                  95Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln Glu Ala Thr Asn            100                 105                 110Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu Lys Lys Trp Phe        115                 120                 125Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu Val Arg Lys Met    130                 135                 140Glu Asp Ser Lys Arg Asn Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly145                 150                 155                 160Gly Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Cys Asp Lys Thr His                165                 170                 175Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            180                 185                 190Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        195                 200                 205Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    210                 215                 220Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys225                 230                 235                 240Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                245                 250                 255Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            260                 265                 270Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        275                 280                 285Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    290                 295                 300Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu305                 310                 315                 320Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                325                 330                 335Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            340                 345                 350Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        355                 360                 365Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    370                 375                 380His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly385                 390                 395                 400Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile                405                 410                 415Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly Glu Arg            420                 425                 430Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His        435                 440                 445Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile Lys Tyr    450                 455                 460Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly465                 470                 475                 480Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser Glu Asp                485                 490                 495Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr Thr Phe            500                 505                 510Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly Gly Gly        515                 520                 525Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu    530                 535                 540Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile545                 550                 555                 560Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val His Trp                565                 570                 575Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp            580                 585                 590Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg Leu Ser        595                 600                 605Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser    610                 615                 620Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr625                 630                 635                 640Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr                645                 650                 655Val Ser Ala</s400><s200><s210>34</s210><s211>659</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 34His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn Gly Ser Asp Thr1               5                   10                  15His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln Ile Ile Thr Phe            20                  25                  30Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met Ile Gly Asp Glu        35                  40                  45Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu Phe Phe Ser Leu    50                  55                  60Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp Leu Thr Tyr Phe65                  70                  75                  80Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe Asp Gln Phe Tyr                85                  90                  95Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln Glu Ala Thr Asn            100                 105                 110Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu Lys Lys Trp Phe        115                 120                 125Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu Val Arg Lys Met    130                 135                 140Glu Asp Ser Lys Arg Asn Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly145                 150                 155                 160Gly Ser Gly Gly Gly Gly Ser Asp Ile Leu Leu Thr Gln Ser Pro Val                165                 170                 175Ile Leu Ser Val Ser Pro Gly Glu Arg Val Ser Phe Ser Cys Arg Ala            180                 185                 190Ser Gln Ser Ile Gly Thr Asn Ile His Trp Tyr Gln Gln Arg Thr Asn        195                 200                 205Gly Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Glu Ser Ile Ser Gly    210                 215                 220Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu225                 230                 235                 240Ser Ile Asn Ser Val Glu Ser Glu Asp Ile Ala Asp Tyr Tyr Cys Gln                245                 250                 255Gln Asn Asn Asn Trp Pro Thr Thr Phe Gly Ala Gly Thr Lys Leu Glu            260                 265                 270Leu Lys Arg Thr Val Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser        275                 280                 285Gly Gly Gly Gly Ser Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu    290                 295                 300Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe305                 310                 315                 320Ser Leu Thr Asn Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys                325                 330                 335Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr            340                 345                 350Asn Thr Pro Phe Thr Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys        355                 360                 365Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ser Asn Asp Thr Ala    370                 375                 380Ile Tyr Tyr Cys Ala Arg Ala Leu Thr Tyr Tyr Asp Tyr Glu Phe Ala385                 390                 395                 400Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly                405                 410                 415Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Cys            420                 425                 430Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly        435                 440                 445Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met    450                 455                 460Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His465                 470                 475                 480Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val                485                 490                 495His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr            500                 505                 510Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly        515                 520                 525Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile    530                 535                 540Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val545                 550                 555                 560Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser                565                 570                 575Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu            580                 585                 590Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro        595                 600                 605Val Leu Asp Ser Asp Gly Ser Phe Ala Leu Tyr Ser Lys Leu Thr Val    610                 615                 620Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met625                 630                 635                 640His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser                645                 650                 655Pro Gly Lys</s400><s200><s210>35</s210><s211>232</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 35Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala1               5                   10                  15Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro            20                  25                  30Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val        35                  40                  45Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val    50                  55                  60Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln65                  70                  75                  80Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln                85                  90                  95Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala            100                 105                 110Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro        115                 120                 125Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr    130                 135                 140Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser145                 150                 155                 160Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr                165                 170                 175Lys Thr Trp Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Thr            180                 185                 190Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe        195                 200                 205Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys    210                 215                 220Ser Leu Ser Leu Ser Pro Gly Lys225                 230</s400><s200><s210>36</s210><s211>659</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 36His Lys Leu Ala Phe Asn Phe Asn Leu Glu Ile Asn Gly Ser Asp Thr1               5                   10                  15His Ser Thr Val Asp Val Tyr Leu Asp Asp Ser Gln Ile Ile Thr Phe            20                  25                  30Asp Gly Lys Asp Ile Arg Pro Thr Ile Pro Phe Met Ile Gly Asp Glu        35                  40                  45Ile Phe Leu Pro Phe Tyr Lys Asn Val Phe Ser Glu Phe Phe Ser Leu    50                  55                  60Phe Arg Arg Val Pro Thr Ser Thr Pro Tyr Glu Asp Leu Thr Tyr Phe65                  70                  75                  80Tyr Glu Cys Asp Tyr Thr Asp Asn Lys Ser Thr Phe Asp Gln Phe Tyr                85                  90                  95Leu Tyr Asn Gly Glu Glu Tyr Thr Val Lys Thr Gln Glu Ala Thr Asn            100                 105                 110Lys Asn Met Trp Leu Thr Thr Ser Glu Phe Arg Leu Lys Lys Trp Phe        115                 120                 125Asp Gly Glu Asp Cys Ile Met His Leu Arg Ser Leu Val Arg Lys Met    130                 135                 140Glu Asp Ser Lys Arg Asn Thr Gly Gly Gly Gly Gly Ser Gly Gly Gly145                 150                 155                 160Gly Ser Gly Gly Gly Gly Ser Glu Pro Lys Ser Cys Asp Lys Thr His                165                 170                 175Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            180                 185                 190Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        195                 200                 205Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    210                 215                 220Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys225                 230                 235                 240Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                245                 250                 255Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            260                 265                 270Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        275                 280                 285Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Ser Pro    290                 295                 300Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Arg Cys His305                 310                 315                 320Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                325                 330                 335Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Lys Pro Val Leu Asp Ser            340                 345                 350Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        355                 360                 365Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu    370                 375                 380His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly385                 390                 395                 400Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile                405                 410                 415Leu Leu Thr Gln Ser Pro Val Ile Leu Ser Val Ser Pro Gly Glu Arg            420                 425                 430Val Ser Phe Ser Cys Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile His        435                 440                 445Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile Lys Tyr    450                 455                 460Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly465                 470                 475                 480Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser Glu Asp                485                 490                 495Ile Ala Asp Tyr Tyr Cys Gln Gln Asn Asn Asn Trp Pro Thr Thr Phe            500                 505                 510Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Gly Gly Gly        515                 520                 525Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu    530                 535                 540Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile545                 550                 555                 560Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr Gly Val His Trp                565                 570                 575Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp            580                 585                 590Ser Gly Gly Asn Thr Asp Tyr Asn Thr Pro Phe Thr Ser Arg Leu Ser        595                 600                 605Ile Asn Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser    610                 615                 620Leu Gln Ser Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Thr625                 630                 635                 640Tyr Tyr Asp Tyr Glu Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr                645                 650                 655Val Ser Ala</s400><s200><s210>37</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 37Gly Gly Gly Gly Ser1               5</s400><s200><s210>38</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      8xHis tag</s223></s220></s200><s400> 38His His His His His His His His1               5</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002451A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221222" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002451</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17774306</doc-number><date>20201106</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>075</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>861</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>14</main-group><subgroup>075</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>861</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2750</main-group><subgroup>14122</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2750</main-group><subgroup>14143</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">VIRAL CAPSID POLYPEPTIDES</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62932646</doc-number><date>20191108</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>PRESIDENT AND FELLOWS OF HARVARD COLLEGE</orgname><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>KELSIC</last-name><first-name>Eric</first-name><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>SINAI</last-name><first-name>Sam</first-name><address><city>Somerville</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>OGDEN</last-name><first-name>Pierce</first-name><address><city>Somerville</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>CHURCH</last-name><first-name>George M.</first-name><address><city>Brookline</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>PRESIDENT AND FELLOWS OF HARVARD COLLEGE</orgname><role>02</role><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/059294</doc-number><date>20201106</date></document-id><us-371c12-date><date>20220504</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The technology described herein provides variant adeno-associated viral capsid polypeptides and viruses comprising the same. Further provided herein are methods for delivering a viral payload using viruses comprising variant capsid polypeptides described herein.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="107.02mm" wi="158.75mm" file="US20230002451A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="214.97mm" wi="159.26mm" orientation="landscape" file="US20230002451A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS-REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application claims benefit under 35 U.S.C. &#xa7; 119(e) of U.S. Provisional Application No. 62/932,646 filed Nov. 8, 2019, the content of which is incorporated herein by reference in its entirety</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?federal-research-statement description="Federal Research Statement" end="lead"?><heading id="h-0002" level="1">GOVERNMENT SUPPORT</heading><p id="p-0003" num="0002">This invention was made with government support under NIH-P50-HG005550 and NIH-RM1-HG008525 awarded by National Institutes of Health. The government has certain rights in the invention.</p><?federal-research-statement description="Federal Research Statement" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0003" level="1">SEQUENCE LISTING</heading><p id="p-0004" num="0003">The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 30, 2019, is named 002806-096400PL01_SL.txt and is 16,548,992 bytes in size.</p><heading id="h-0004" level="1">TECHNICAL FIELD OF THE INVENTION</heading><p id="p-0005" num="0004">This invention is related to engineering viral vectors.</p><heading id="h-0005" level="1">BACKGROUND OF THE INVENTION</heading><p id="p-0006" num="0005">Adeno-associated virus (AAV) is an attractive agent for use as gene delivery vector. Its simple structure also makes it an attractive target for genetic improvement programs. Nonetheless, there is a continuing need in the art to improve delivery of DNA using AAV and other viral vectors.</p><heading id="h-0006" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0007" num="0006">Described herein are viral vectors comprising a variant sequence of the capsid gene, VP1. Such vectors provide, e.g., an improvement in the degree of tissue targeting, payload packaging, delivery efficiency, etc., attainable with such vectors. In particular, viral vectors with capsid polypeptide mutations that modify tropism of the viral particles relative to particles with wild-type capsid polypeptide are described.</p><p id="p-0008" num="0007">Accordingly, one aspect provided herein is a viral capsid polypeptide bearing a mutation relative to SEQ ID NO: 2 (WT AAV2) in a region corresponding to amino acids 561-588.</p><p id="p-0009" num="0008">In one embodiment of any aspect provided herein, the region corresponding to amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0010" num="0009">In one embodiment of any aspect provided herein, the capsid is an AAV capsid. In one embodiment of any aspect provided herein, the capsid is an AAV2 capsid.</p><p id="p-0011" num="0010">In one embodiment of any aspect provided herein, the only variation relative to a wild-type AAV viral capsid is in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0012" num="0011">Another aspect described herein provides an AAV VP1 capsid polypeptide bearing a mutation in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0013" num="0012">In one embodiment of any aspect provided herein, the region corresponding to amino acids 561-588 of SEQ ID NO: 2 comprises a sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0014" num="0013">In one embodiment of any aspect provided herein, the AAV VP1 polypeptide described herein is an AAV2 capsid polypeptide.</p><p id="p-0015" num="0014">Another aspect described herein provides a viral capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0016" num="0015">Another aspect described herein provides a variant of the viral capsid polypeptide of SEQ ID NO: 2, wherein the region of amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0017" num="0016">Another aspect described herein provides an AAV2 capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0018" num="0017">Another aspect described herein provides an engineered AAV vector having at least one viral capsid polypeptide comprising any of the capsid polypeptides described herein.</p><p id="p-0019" num="0018">Another aspect described herein provides a nucleic acid encoding any of the capsid polypeptide described herein.</p><p id="p-0020" num="0019">Another aspect described herein provides a viral particle comprising any of the capsid polypeptide described herein.</p><p id="p-0021" num="0020">Another aspect described herein provides a method for delivering a payload, the method comprising contacting a cell with any of the engineered AAV vectors described herein, or any of the viral particles described herein.</p><p id="p-0022" num="0021">In one embodiment of any aspect provided herein, the contacting is sufficient to allow for expression of the payload in the cell.</p><p id="p-0023" num="0022">Another aspect described herein provides a method for administering a payload, the method comprising administering to a subject any of the engineered AAV vectors described herein, or any of the viral particles described herein.</p><p id="p-0024" num="0023">In one embodiment of any aspect provided herein, the administering is sufficient to allow for expression of the payload in the cell.</p><p id="p-0025" num="0024">In one embodiment of any aspect provided herein, the payload is selected from the group consisting of: a nucleic acid, a polypeptide, an inhibitory RNA, an antibody or antibody reagent, an oligonucleotide, and an miRNA.</p><p id="p-0026" num="0025">In yet another aspect, provided herein is a cell comprising a variant capsid polypeptide described herein or a polynucleotide encoding same. For example, a cell comprising a viral particle, where the viral particle comprises a variant capsid polypeptide described herein.</p><p id="p-0027" num="0026">In still another aspect provided herein is a composition, e.g., a pharmaceutical composition comprising a variant capsid polypeptide described herein or a polynucleotide encoding same.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0007" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a plot showing the proportion of attempted variants that demonstrate viable packaging ability using each method (VAE and DeepSearch). We include as baseline the success of random sampling for comparison.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0008" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0029" num="0028">Described herein are viral vectors containing amino acid mutations in the capsid protein, VP1. Such vectors provide improvements in various functions of the viral vector, e.g., improvement in the degree of tissue targeting (e.g., tropism), payload packaging, delivery efficiency, etc. relative to vectors with wild-type capsid polypeptide. Alternatively, a viral vector comprising a mutated VP1 sequence has a decreased function, e.g., reduced or broadened tropism, relative to vectors with wild-type capsid polypeptide. In one embodiment, a viral vector comprising a mutated VP1 polypeptide comprises an improvement or reduction in at least two functions of the viral vector.</p><p id="p-0030" num="0029">Mutations can be combined together in a single viral nucleic acid or a single viral protein sequence for improved properties. The following describes mutations to viral capsid polypeptides that permit viral genome packaging, yet modify viral vector function, including but not limited to, tropism, either positively, negatively, or both when mutations are combined, relative to given tissues or cell types. Also described are methods of using mutated viral capsid polypeptides and viral vectors comprising them to introduce nucleic acids to desired tissue or cell types, e.g., with improved selectivity for those tissue or cell types. The following provides description of various mutations and considerations for their use to generate viral vectors with improved properties. Mutant capsid proteins and nucleic acids encoding them can be used, e.g., for further viral improvement, for virus preparation and manufacture, and for safety and efficacy studies.</p><heading id="h-0009" level="2">Mutant Capsid Polypeptides</heading><p id="p-0031" num="0030">One aspect of the technology described herein provides a viral capsid polypeptide bearing a mutation relative to SEQ ID NO: 2 in a region that corresponds to amino acids 561-588 (SEQ ID NO: 3). SEQ ID NO: 2 is an amino acid sequence encoding wild-type AAV2 capsid protein.</p><p id="p-0032" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;2)</entry></row><row><entry>MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLV</entry></row><row><entry> </entry></row><row><entry>LPGYKYLGPFNGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLK</entry></row><row><entry> </entry></row><row><entry>YNHADAEFQERLKEDTSFGGNLGRAVFQAKKRVLEPLGLVEEPVKTA</entry></row><row><entry> </entry></row><row><entry>PGKKRPVEHSPVEPDSSSGTGKAGQQPARKRLNFGQTGDADSVPDPQ</entry></row><row><entry> </entry></row><row><entry>PLGQPPAAPSGLGTNTMATGSGAPMADNNEGADGVGNSSGNWHCDS</entry></row><row><entry> </entry></row><row><entry>TWMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPW</entry></row><row><entry> </entry></row><row><entry>GYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQN</entry></row><row><entry> </entry></row><row><entry>DGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQ</entry></row><row><entry> </entry></row><row><entry>YGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHS</entry></row><row><entry> </entry></row><row><entry>SYAHSQSLDRLMNPLIDQYLYYLSRTNTPSGTTTQSRLQFSQAGASDIR</entry></row><row><entry> </entry></row><row><entry>DQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSLV</entry></row><row><entry> </entry></row><row><entry>NPGPAMASHKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITDEEEIR</entry></row><row><entry> </entry></row><row><entry>TTNPVATEQYGSVSTNLQRGNRQAATADVNTQGVLPGMVWQDRDV</entry></row><row><entry> </entry></row><row><entry>YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTF</entry></row><row><entry> </entry></row><row><entry>SAAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVN</entry></row><row><entry> </entry></row><row><entry>VDFTVDTNGVYSEPRPIGTRYLTRNL</entry></row></tbody></tgroup></table></tables></p><p id="p-0033" num="0031">SEQ ID NO: 3 is an amino acid sequence encoding the amino acid region between amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0034" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="49pt" align="left"/><colspec colname="1" colwidth="168pt" align="right"/><tbody valign="top"><row><entry/><entry>(SEQ&#x2003;ID&#x2003;NO:&#x2003;3)</entry></row><row><entry/><entry>DEEEIRTTNPVATEQYGSVSTNLQRGNR</entry></row></tbody></tgroup></table></tables></p><p id="p-0035" num="0032">In one embodiment, the region corresponding to amino acids 561-588 comprises a sequence selected from SEQ ID NO:4-41,337.</p><p id="p-0036" num="0033">In one embodiment, the capsid is an AAV capsid. In one embodiment, the capsid is an AAV2 capsid.</p><p id="p-0037" num="0034">Further provided herein is an AAV VP1 capsid polypeptide bearing a mutation in the region corresponding to amino acids 561-588 of SEQ ID NO: 2. In one embodiment, the region corresponding to amino acids 561-588 of SEQ ID NO: 2 comprises a sequence selected from SEQ ID NO: 4-41,337. In one embodiment of any aspect provided herein, the AAV VP1 polypeptide described herein is an AAV2 capsid polypeptide.</p><p id="p-0038" num="0035">Further provided herein is a viral capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 comprises a sequence SEQ ID NO: 4-41,337.</p><p id="p-0039" num="0036">Further provided herein is a variant of the viral capsid polypeptide of SEQ ID NO: 2, wherein the region of amino acids 561-588 comprises a sequence of SEQ ID NO: 4-41,337.</p><p id="p-0040" num="0037">Viruses are typically tropic for certain types of cells and or tissues in the natural host. In one embodiment, a mutant (i.e., variant) sequence of VP1 described herein alters tropism of the virus comprising the variant sequence. As used herein the term &#x201c;alters tropism&#x201d; refers to a mutation or set of mutations that changes the efficiency with which a viral vector delivers a nucleic acid to a given tissue or cell type, e.g., blood, brain, heart, kidney, liver, lung, or spleen, among others. In other words, a viral vector comprising a variant viral capsid polypeptide described herein exhibits altered characteristics in comparison to a viral vector comprising the wild-type capsid polypeptide, e.g., a polypeptide of SEQ ID NO: 2, including but not limited to, altered cellular or tissue tropism, cellular or tissue transduction, and/or antigenic properties.</p><p id="p-0041" num="0038">The tropism of a virus or viral vector is generally defined by the structure of its outer surface that interacts with receptors or other cell surface determinants on target cells. For AAV vectors, among others, viral vector tropism is determined primarily by viral capsid polypeptides, and as described herein, the tropism of such vectors can be changed by changing the amino acid sequence of the viral capsid polypeptide. An amino acid change that changes the efficiency of viral vector delivery of a nucleic acid to a target cell or tissue type by at least 10% relative to a reference vector, often, but not necessarily relative to a wild-type vector, is an altered tropism. To be clear, an altered tropism can be an increase/enrichment by at least 10% (1.1&#xd7;) or a decrease/de-enrichment by at least 10% (0.9&#xd7;).</p><p id="p-0042" num="0039">The term &#x201c;tropism&#x201d; refers to the ability of a viral vector to infect one or more specified cell types, but can also encompass how the vector functions to transduce the cell in the one or more specified cell types. In other words, tropism refers to preferential entry of the viral vector into certain cell or tissue type(s) and/or preferential interaction with the cell surface that facilitates entry into certain cell or tissue types, optionally and preferably followed by expression (e.g., transcription and, optionally, translation) of a transgene carried by the viral vector/particle in the cell. As used herein, the term &#x201c;tropism profile&#x201d; refers to the pattern of transduction of one or more target cells, tissues and/or organs.</p><p id="p-0043" num="0040">As used herein, the term &#x201c;transduction&#x201d; refers to the introduction, by a viral vector, of a genetic payload and expression of one or more genes encoded therein. Thus, transduction refers to entry of the vector into the cell and the transfer of genetic material contained within the vector into the cell to obtain expression from the vector genome. In some cases, but not all cases, transduction and tropism may correlate.</p><p id="p-0044" num="0041">As used here, &#x201c;systemic tropism&#x201d; and &#x201c;systemic transduction&#x201d; (and equivalent terms) indicate that the viral vector exhibits tropism for or transduces, respectively, tissues throughout the body (e.g., brain, lung, skeletal muscle, heart, liver, kidney and/or pancreas).</p><p id="p-0045" num="0042">Methods for measuring viral vector tropism are known in the art. For example, viral vector tropism can be determined by measuring the ability of viral vector to transduce transgene in a cell of interest. This can be measured by the expression of a reporter protein and compared to a control viral vector, e.g., wild-type viral vector. Some exemplary reporter proteins include, but are not limited to, GFP, YFP, red cherry, &#x3b2;-galactosidase, or other reporter proteins known in the art.</p><p id="p-0046" num="0043">In one embodiment, the mutation of the capsid polypeptide increases tropism, e.g., the virus comprising the mutated viral capsid polypeptide more efficiently delivers nucleic acid to the target cell type as compared a virus comprising a wild-type, or other reference, viral capsid polypeptide. In one embodiment, tropism is at least 1.1-fold (e.g., 10% greater than reference level, or 110% of the level reference level) more efficient as compared to a wild-type, or other reference, viral capsid polypeptide. In one embodiment, the delivery of a nucleic acid is at least 1.5-fold, at least 2-fold, at least 4-fold, at least 5-fold, at least 10-fold, or more, more efficient as compared to a virus comprising the wild-type viral capsid polypeptide. One of ordinary skill in the art can measure the delivery efficiency of a viral particle comprising any of the viral capsid polypeptides described herein, e.g., using PCR-based assays on an isolated targeted cell or tissue type (e.g., blood, heart, kidney, liver, lung, or spleen) to assess if the nucleic acid is delivered to and/or expressed in that targeted cell type. The expression of the nucleic acid delivered by a viral particle comprising either a viral capsid polypeptide as described herein or a wild-type, or other reference, viral capsid polyprotein can be compared to determine the change in expression as a measure of the efficiency of delivery.</p><p id="p-0047" num="0044">In some embodiments of any one of the aspects, a viral vector comprising a variant viral capsid polypeptide as described herein exhibits increased tropism, as compared to a wild-type, or other reference, viral capsid polypeptide, for a cell or tissue selected from skeletal muscle, cardiac muscle, diaphragm muscle, pancreas (including (&#x3b2;-islet spleen, the gastrointestinal tract (e.g., epithelium and/or smooth muscle), cells of the central nervous system, liver, lung, joint cells, and/or kidney. For example, a viral vector comprising a variant viral capsid polypeptide as described herein exhibits increased tropism for a tissue or cell type selected from blood, brain, heart, kidney, liver, lung, and spleen.</p><p id="p-0048" num="0045">In one embodiment, the mutation of the capsid polypeptide decreases tropism, e.g., the virus comprising the mutated viral capsid polypeptide delivers nucleic acid to a broader range of target cell types as compared to a virus comprising the wild-type, or other reference, viral capsid polypeptide. In one embodiment, the tropism is decreased by at least 10%. In other embodiments, the tropism is decreased by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99%, or more as compared to a virus comprising the wild-type, or other reference, viral capsid polypeptide. One skilled in the art can assess tropism of a virus using standard techniques, e.g., measuring local expression of a virus following in vivo delivery.</p><p id="p-0049" num="0046">In some embodiments of any one of the aspects, a viral vector comprising a variant viral capsid polypeptides described herein exhibits a decreased tropism, as compared to a wild-type, or other reference, viral capsid polypeptide, for a cell or tissue selected from skeletal muscle, cardiac muscle, diaphragm muscle, pancreas (including (&#x3b2;-islet cells), spleen, the gastrointestinal tract (e.g., epithelium and/or smooth muscle), cells of the central nervous system, liver, lung, joint cells, and/or kidney. For example, a viral vector comprising a variant viral capsid polypeptides described herein exhibits decreased tropism for a tissue or cell type selected from blood, brain, heart, kidney, liver, lung, and spleen.</p><p id="p-0050" num="0047">Variant VP1 polypeptides have been identified and assessed for effects on viral DNA packaging and viral infectivity of particular tissues. In one embodiment, the viral packaging is increased by at least 10%. In other embodiments, the viral packaging is increased or altered by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99%, or more as compared to a virus comprising the wild-type, or other reference, viral capsid polypeptide.</p><p id="p-0051" num="0048">In one embodiment, the viral packaging is decreased by at least 10%. Alterations in packaging include, but are not limited to alterations in the rate or efficiency of packaging, or, for example, alterations in the amount of vector sequence that can be packaged while retaining viral infectivity. In one embodiment, the viral infectivity is increased by at least 10% or more. In one embodiment, the viral infectivity is increased by 10%. In other embodiments, the viral infectivity is increased by 20%, 30%, 40%, 50%, or more as compared to a virus comprising the wild-type viral capsid polypeptide. In one embodiment, the viral infectivity is decreased by at least 10%. In other embodiments, the viral infectivity is decreased by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99%, or more as compared to a virus comprising the wild-type, or other reference, viral capsid polypeptide. A decreased in infectivity can be tolerated, e.g., where there are other beneficial changes provided by the mutation. Viral packaging and infectivity can be assessed by one skilled in the art using standard techniques, e.g., measuring the viral titer in a sample that has been contacted with an AAV virus or viral particle comprising any of the viral capsid polypeptides described herein.</p><p id="p-0052" num="0049">Particular regions of AAV2 capsid protein tolerate amino acid alterations, e.g., deletion, insertion, or substitution better than others, and changes to certain regions that tolerate such change can have pronounced impact on viral vector tropism, among other functions. The region of the AAV2 capsid polypeptide of SEQ ID NO: 3, which is amino acids 561-588 of SEQ ID NO: 2, is identified herein as being tolerant of a variety of changes.</p><p id="p-0053" num="0050">One aspect of the technology described herein is a nucleic acid, e.g., a polynucleotide encoding any of the viral capsid polypeptides described herein. One skilled in the art can alter the wild-type VP1 sequence (SEQ ID NO: 1), e.g., by introducing at least one base pair substitution, such that the altered sequence encodes a variant amino acid sequence. The nucleic acid sequence for each codon is known in the art and presented herein in Table 1. For example, to alter an amino acid from an isoleucine (which is translated by the nucleotide sequence AUU) to valine (which is translated by the nucleotide sequence GUU), one would change the first nucleotide from an A to G. In one embodiment, the nucleic acid sequence of SEQ ID NO: 1 is altered such that the region of amino acids 561-588 of the altered sequence encodes a sequence of SEQ ID NO: 4-41,337. Site-directed mutagenesis is known in the art and can be used to introduce a point mutation(s) (e.g., amino acid substitutions, insertions, or deletions) or other mutations or combinations thereof to a viral capsid polypeptide. Site-directed mutagenesis is further described in, e.g., Li B, et al. <i>Hum Gene Ther Methods. </i>2015 December: 26(6):211-20, and Bachman, <i>J. Methods Enzymol. </i>2013; 529:241-248, which are incorporated herein by reference in their entireties.</p><p id="p-0054" num="0051">In one embodiment, the nucleotide sequence comprises at least 1 point mutation. In one embodiment, the nucleotide sequence comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 or more point mutations.</p><p id="p-0055" num="0052">In some embodiments, the nucleotide sequence comprises no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 11, no more than 12, no more than 13, no more than 14, no more than 15, no more than 16, no more than 17, no more than 18, no more than 19, no more than 20, no more than 21, no more than 22, no more than 23, no more than 24, no more than 25, no more than 26, no more than 27, no more than 28, no more than 29, no more than 30, no more than 31, no more than 32, no more than 33, no more than 34, no more than 35, no more than 36, no more than 37, no more than 38, no more than 39, no more than 40, no more than 41, no more than 42, no more than 43, no more than 44, no more than 45, no more than 46, no more than 47, no more than 48, no more than 49, no more than 50, no more than 51, no more than 52, no more than 53, no more than 54, no more than 55, no more than 56, no more than 57, no more than 58, no more than 59, no more than 60, no more than 61, no more than 62, no more than 63, no more than 64, no more than 65, no more than 66, no more than 67, no more than 68, no more than 69, no more than 70, no more than 71, no more than 72, no more than 73, no more than 74, no more than 75, no more than 76, no more than 77, no more than 78, no more than 79, no more than 80, no more than 81, no more than 82, no more than 83, or no more than 84 point mutations.</p><p id="p-0056" num="0053">In one embodiment, the nucleotide sequence comprises at least 1 point mutation in the region encoding amino acids 561-588 of SEQ ID NO: 2. For example, the nucleotide sequence comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, or 84 point mutations in the region encoding amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0057" num="0054">In some embodiments, the nucleotide sequence comprises no more than 1, no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 11, no more than 12, no more than 13, no more than 14, no more than 15, no more than 16, no more than 17, no more than 18, no more than 19, no more than 20, no more than 21, no more than 22, no more than 23, no more than 24, no more than 25, no more than 26, no more than 27, no more than 28, no more than 29, no more than 30, no more than 31, no more than 32, no more than 33, no more than 34, no more than 35, no more than 36, no more than 37, no more than 38, no more than 39, no more than 40, no more than 41, no more than 42, no more than 43, no more than 44, no more than 45, no more than 46, no more than 47, no more than 48, no more than 49, no more than 50, no more than 51, no more than 52, no more than 53, no more than 54, no more than 55, no more than 56, no more than 57, no more than 58, no more than 59, no more than 60, no more than 61, no more than 62, no more than 63, no more than 64, no more than 65, no more than 66, no more than 67, no more than 68, no more than 69, no more than 70, no more than 71, no more than 72, no more than 73, no more than 74, no more than 75, no more than 76, no more than 77, no more than 78, no more than 79, no more than 80, no more than 81, no more than 82, no more than 83, or no more than 84 point mutations in the region encoding amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0058" num="0055">In one embodiment, the nucleic acid sequence is altered such that it encodes at least 1 variant amino acid. In one embodiment, the nucleic acid sequence is altered such that it encodes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or more variant amino acids. For clarity, it is noted that a variant amino acid means an amino acid that is different from the one encoded by a nucleic acid sequence encoding SEQ ID NO: 2.</p><p id="p-0059" num="0056">In some embodiments, the nucleic acid sequence is altered such that it encodes no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 11, no more than 12, no more than 13, no more than 14, no more than 15, no more than 16, no more than 17, no more than 18, no more than 19, no more than 20, no more than 21, no more than 22, no more than 23, no more than 24, no more than 25, no more than 26, no more than 27, or no more than 28 variant amino acids.</p><p id="p-0060" num="0057">In one embodiment, the nucleic acid sequence is altered such that it encodes at least 1 variant amino acid in the region corresponding to amino acids 561-588 of SEQ ID NO: 2. For Example, the nucleic acid sequence is altered such that it encodes at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or more variant amino acids in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0061" num="0058">In some embodiments, the nucleic acid sequence is altered such that it encodes no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 11, no more than 12, no more than 13, no more than 14, no more than 15, no more than 16, no more than 17, no more than 18, no more than 19, no more than 20, no more than 21, no more than 22, no more than 23, no more than 24, no more than 25, no more than 26, no more than 27, or no more than 28 variant amino acids in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0062" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Nucleotide codons for amino acids</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="140pt" align="left"/><tbody valign="top"><row><entry/><entry>AA</entry><entry>Codons</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>Ala</entry><entry>GCT, GCC, GCA, GCG</entry></row><row><entry/><entry>Arg</entry><entry>CGT, CGC, CGA, CGG, AGA, AGG</entry></row><row><entry/><entry>Asn</entry><entry>AAT, AAC</entry></row><row><entry/><entry>Asp</entry><entry>GAT, GAC</entry></row><row><entry/><entry>Cys</entry><entry>TGT, TGC</entry></row><row><entry/><entry>Gln</entry><entry>CAA, CAG</entry></row><row><entry/><entry>Glu</entry><entry>GAA, GAG</entry></row><row><entry/><entry>Gly</entry><entry>GGT, GGC, GGA, GGG</entry></row><row><entry/><entry>His</entry><entry>CAT, CAC</entry></row><row><entry/><entry>Ile</entry><entry>ATT, TAC, ATA</entry></row><row><entry/><entry>Leu</entry><entry>TTA, TTG, CTT, CTA, CTG</entry></row><row><entry/><entry>Lys</entry><entry>AAA, AAG</entry></row><row><entry/><entry>Met</entry><entry>ATG</entry></row><row><entry/><entry>Phe</entry><entry>TTT, TTC</entry></row><row><entry/><entry>Pro</entry><entry>CCT, CCC, CCA, CCG</entry></row><row><entry/><entry>Ser</entry><entry>TCT, TCC, TCA, TCG, AGT, AGC</entry></row><row><entry/><entry>Thr</entry><entry>ACT, ACC, ACA, ACG</entry></row><row><entry/><entry>Trp</entry><entry>TGG</entry></row><row><entry/><entry>Tyr</entry><entry>TAT, TAC</entry></row><row><entry/><entry>Val</entry><entry>GTT, GTC, GTA, GTG</entry></row><row><entry/><entry>Start</entry><entry>ATG</entry></row><row><entry/><entry>Stop</entry><entry>TAA, TGA, TAG</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0063" num="0059">In some embodiments, a polynucleotide encoding a variant viral capsid polypeptide described herein is operably linked to a promoter sequence, for example, a promoter sequence that drives expression of the polynucleotide in a cell. In some embodiments, the polynucleotide further comprises a sequence that encodes a REP protein, e.g., an AAV rep protein. In some embodiments, the polynucleotide further comprises a sequence that encodes a CAP protein, e.g., an AAV CAP protein.</p><p id="p-0064" num="0060">Another aspect of the technology described herein is a viral particle comprising any of the viral capsid polypeptides described herein. It is noted that a viral particle comprising a variant capsid polypeptide as described herein can be replication-competent or replication-incompetent. Thus, in some embodiments, the viral particle comprising a variant capsid polypeptide as described herein is replication-competent. As used herein, the term &#x201c;replication-competent&#x201d; refers to a virus or viral particle that is infectious, and is also capable of being replicated in an infected cell (i.e. in the presence of a helper virus or helper virus functions). In the case of AAV, replication competence generally requires the presence of functional AAV packaging genes.</p><p id="p-0065" num="0061">In some other embodiments, the viral particle comprising a variant capsid polypeptide as described herein is replication-incompetent or replication defective. As used herein, the terms &#x201c;replication-incompetent&#x201d; and &#x201c;replication defective&#x201d; refer to a virus or viral particle that cannot independently replicate and package its genome. For example, when a cell is infected with the virus or viral particle, the heterologous gene is expressed in the infected cells, however, the virus or the viral particle is not able to replicate further.</p><p id="p-0066" num="0062">In some embodiments, the viral particle further comprises a polynucleotide encoding a transgene, e.g., a polynucleotide comprising a sequence that encodes a gene product such as a therapeutic gene product. In some embodiments, the polynucleotide is flanked on the 5&#x2032; and 3&#x2032; ends by functional AAV inverted terminal repeat (ITR) sequences. By &#x201c;functional AAV ITR sequences&#x201d; is meant that the ITR sequences function as intended for the rescue; replication and packaging of the AAV virion. Hence; AAV ITRs for use in the gene delivery vectors need not have a wild-type nucleotide sequence, and can be altered by the insertion, deletion or substitution of nucleotides or the AAV ITRs can be derived from any of several AAV serotypes, e.g. AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAV10. In some embodiments, the viral particles have the wild type REP and CAP genes deleted in whole or part, but retain functional flanking ITR sequences.</p><p id="p-0067" num="0063">One skilled in the art can make viral particles comprising a variant capsid polypeptide described herein using standard methods. For example, an AAV expression vector comprising a polynucleotide cassette can be introduced into a producer cell, followed by introduction of an AAV helper construct comprising a polynucleotide sequence encoding a variant capsid polypeptide described herein, and where the helper construct includes AAV coding regions capable of being expressed in the producer cell and which complement AAV helper functions absent in the AAV vector. This is followed by introduction of helper virus and/or additional vectors into the producer cell, wherein the helper virus and/or additional vectors provide accessory functions capable of supporting efficient rAAV virus production. The producer cells are then cultured to produce rAAV. Some exemplary methods for producing viral particles amenable to the presently disclosed technology are described, for example, in U.S. Pat. Nos. 5,436,146; 5,753,500; 6,040,183, 6,093,570 and 6,548,286, contents of each of which is incorporated herein by reference in their entireties.</p><p id="p-0068" num="0064">In one example, viral particles comprising a variant polypeptide described herein can be produced by first generating a DNA library of AAV capsid variants. Libraries of AAV2 capsid gene sequence variants are cloned into a plasmid containing the AAV Inverted Terminal Repeat regions (ITRs). The final ITR plasmids contain, e.g., a cytomegalovirus (CMV) promoter upstream of the Cap gene. AAV virus libraries are produced from the DNA libraries. The capsid library plasmids, AAV pHelper plasmids, and plasmids containing the AAV2 Rep gene are co-transfected into HEK-293T cells using PEI. Capsids are purified using standard techniques for cell lysis (freeze-thaw or addition of 5 M NaCl), treatment with benzonase to remove unpackaged genomes, and purification and concentration by iodixanol ultra-centrifugation.</p><p id="p-0069" num="0065">In preparing the viral particles, any host cells for producing recombinant viral particles can be employed, including, for example, mammalian cells, insect cells, plant cells, microorganisms and yeast. Host cells can also be packaging cells in which the AAV rep and cap genes are stably maintained in the host cell or producer cells in which the AAV vector genome is stably maintained and packaged. Exemplary packaging and producer cells include but are not limited to HeLa cells, COS cells, COS-1 cells, COS-7 cells, HEK293 cells, A549 cells, MK cells, BSC-1 cells, BSC-40 cells, Vero cells, Sfc9 cells, Sf-21 cells, Tn-368 cells, (High-Five) cells, Saos cells, C2C12 cells, L cells, HT1080 cells, HepG2 cells, WEHI cells, 3T3 cells, 10T1/2 cells, MDCK cells, BMT-10 cells, WI38 cells, or primary fibroblast, hepatocyte or myoblast cells derived from mammals.</p><p id="p-0070" num="0066">In vivo packaging ability of viral capsid variants was measured, e.g., using methods described herein above. The number of viruses that were packaged (&#x201c;virus&#x201d;) compared to the number of input viral genomes (&#x201c;plasmid&#x201d;) were determined. Measuring the frequency of capsid (or other library component) mutants before and after selection reveals which mutations are beneficial and which are deleterious based on the particular selection method.</p><p id="p-0071" num="0067">Also provided herein is a cell comprising a variant viral capsid polypeptide described herein or a polynucleotide encoding a variant viral capsid polypeptide described herein. The cell can be a prokaryotic cell or a eukaryotic cell. For example, the cell can be a mammalian cell, insect cell, plant cell, bacterial cell or yeast cell. Some exemplary cells include, but are not limited to, alveolar cells, basophils, cardiac smooth muscle cells, cardiomyocytes, collecting duct intercalated cells, collecting duct principal cells, ectodermal cells, endocardial cells, endoderm cells, eosinophils, epithelial cells, hepatic stellate cells, interstitial kidney cells, intrahepatic lymphocytes, kidney distal tubule cells, kidney glomerulus parietal cells, kidney glomerulus podocytes, kidney proximal tubule brush border cells, loop of Henle thin segment cells, lung epithelial cells, lung smooth muscle cells, lymphocytes, monocytes, muscle cells, neutrophils, non-parenchymal cells, parenchymal cells, phagocytic Kupffer cells, platelets, red blood cells, sinusoidal endothelial cells, splenic endothelial cells, splenic fibroblasts, splenocytes, and thick ascending limb cells.</p><p id="p-0072" num="0068">In some embodiments, the cell can be a cell used for producing a viral particle, e.g., a producer cell.</p><p id="p-0073" num="0069">In some embodiments, the cell can be a cell which has been transduced, infected, transfected or transformed with a viral vector described herein. Typically, a cell is referred to as &#x201c;transduced&#x201d;, &#x201c;infected&#x201d;; &#x201c;transfected&#x201d; or &#x201c;transformed&#x201d; dependent on the means used for administration, introduction or insertion of heterologous DNA (i.e., the viral vector) into the cell.</p><p id="p-0074" num="0070">Also provided herein are pharmaceutical compositions comprising a variant capsid polypeptide described herein or a polynucleotide encoding same and one or more pharmaceutically acceptable diluent, carrier, or excipient. For example, the composition can comprise a viral particle comprising a variant capsid polypeptide described herein. In some embodiments, the composition can comprise a cell, wherein the cell comprises a variant capsid polypeptide described herein or a polynucleotide encoding same.</p><p id="p-0075" num="0071">For example, the variant capsid polypeptide or a polynucleotide encoding same (as is or as encompassed in a viral particle or cell) can be combined with pharmaceutically-acceptable carriers, diluents and reagents useful in preparing a formulation that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for primate use. Such excipients can be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous. Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. Supplementary active compounds can also be incorporated into the formulations. Solutions or suspensions used for the formulations can include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates; detergents such as Tween 20 to prevent aggregation; and compounds for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. In particular embodiments, the pharmaceutical compositions are sterile. For instances in which ocular cells are to be contacted in vivo, the subject polynucleotide cassettes or gene delivery vectors comprising the subject polynucleotide cassette can be treated as appropriate for delivery to the eye.</p><p id="p-0076" num="0072">Pharmaceutical compositions can further include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, or phosphate buffered saline PBS). In some cases, the composition is sterile and should be fluid to the extent that easy syringability exists. In certain embodiments, it is stable under the conditions of manufacture and storage and is preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be, e.g., a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the internal compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.</p><heading id="h-0010" level="2">Corresponding Mutations</heading><p id="p-0077" num="0073">Mutations at corresponding locations in, for example homologous viral capsid polypeptides, would be expected to have similar effects on viral function. Corresponding locations can include, for example, a location relative to the full length capsid polypeptide (e.g., SEQ ID NO: 2), or for that matter, a location relative to a sub-domain or sub-region of the full length capsid polypeptide (e.g., SEQ ID NO: 3). In one aspect, a viral capsid polypeptide is provided herein that bears a mutation that corresponds to a mutation of the polypeptide of SEQ ID NO: 2, e.g., SEQ ID NO: 4-41,337, as described herein. In one embodiment, a homologous viral capsid polypeptide has at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to wild-type AAV2 capsid protein (e.g., SEQ ID NO: 2). In another embodiment, the viral capsid polypeptides of AAV serotypes 1, and 3-13 are homologous to an AAV2 capsid polypeptide.</p><p id="p-0078" num="0074">One aspect described herein is a viral capsid polypeptide comprising a region corresponding to the amino acid sequence of SEQ ID NO: 3, wherein the region corresponding to the amino acid sequence of SEQ ID NO: 3 comprises a mutation relative to SEQ ID NO: 3 that, e.g., alters the function of the virus comprising the viral capsid polypeptide, wherein the mutation is selected from SEQ ID NO: 4-41,337. In one embodiment, a homologous viral capsid polypeptide has a region with at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more sequence identity to SEQ ID NO: 3.</p><p id="p-0079" num="0075">As noted elsewhere herein, the identification of amino acid sites or regions of amino acid sequence in the AAV2 capsid polypeptide of SEQ ID NO: 2 that tolerate change in general, i.e., that permit functions of the viral vector can be used to guide changes in the capsid polypeptides of other AAV serotypes to similarly influence function or provide for modified properties. Thus, through use of sequence alignment, a mutation or set of mutations that provides a desired change in function for AAV2 capsid polypeptide of SEQ ID NO: 2 can be introduced to the corresponding location of the capsid polypeptide of another AAV serotype to similarly influence those properties in that serotype. It is contemplated that the introduction of changes identified herein in this amino acid 561-588 sub-region of the AAV2 capsid polypeptide to the corresponding region or sub-region of another AAV serotype capsid polypeptide will influence the function of that AAV serotype in a similar manner.</p><p id="p-0080" num="0076">As used herein, &#x201c;mutation&#x201d; refers to any change in the amino acid sequence, e.g., a substitution, insertion, or deletion of at least one amino acid. Site-directed mutations in the nucleic acid sequence can be generated by one skilled in the art using techniques known in the art or described herein.</p><p id="p-0081" num="0077">Mutations that are at equivalent positions in other homologous viruses can be made and used for improving, e.g., virus packaging and virus infectivity. Examples of other homologous viruses include any of AAV serotypes 1, and 3-12, as well as other natural isolates or synthetic sequences. Corresponding positions in homologous viruses can be inferred from sequence homology to AAV2. In one embodiment, the mutations described herein are introduced into the corresponding amino acid sequence of an AAV1, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13 capsid polypeptide.</p><heading id="h-0011" level="2">Methods for Delivering Nucleic Acid</heading><p id="p-0082" num="0078">Provided herein is a method of delivering a payload to a cell comprising contacting a cell with an AAV virus or viral particle comprising any of the viral capsid polypeptides described herein. In one embodiment, the contacting occurs in vitro. In one embodiment, the contacting occurs ex vivo.</p><p id="p-0083" num="0079">The term &#x201c;contacting&#x201d; or &#x201c;contact&#x201d; as used herein in connection with contacting a cell with an AAV virus or viral particle includes subjecting the cell to an appropriate culture medium which comprises the AAV virus or viral particle. Where the cell is in vivo, &#x201c;contacting&#x201d; or &#x201c;contact&#x201d; includes administering the AAV virus or viral particle in a pharmaceutical composition to a subject via an appropriate administration route such that the virus or viral particle contacts the cell in vivo.</p><p id="p-0084" num="0080">Further provided herein is a method of delivering a payload in vivo to a target cell, comprising administering an AAV virus or viral particle comprising any of the viral capsid polypeptides described herein to a subject. In one embodiment, in vivo is systemic delivery.</p><p id="p-0085" num="0081">Exemplary target or host cells include blood cells (e.g., red blood cells, platelets, neutrophils, eosinophils, basophils, lymphocytes, or monocytes); heart cells (e.g., cardiomyocyte, endocardial cells, or cardiac smooth muscle cells); muscle cells; epithelial cells; endoderm cells; ectodermal cells; kidney cells (e.g., kidney glomerulus parietal cells, kidney glomerulus podocytes, kidney proximal tubule brush border cells, loop of Henle thin segment cells, thick ascending limb cells, kidney distal tubule cells, collecting duct principal cells, collecting duct intercalated cells, and interstitial kidney cells); liver cells (e.g., parenchymal cells, non-parenchymal cells, sinusoidal endothelial cells, phagocytic Kupffer cells, hepatic stellate cells, and intrahepatic lymphocytes); lung cells (e.g., lung epithelial cells, lung smooth muscle cells, and alveolar cells); and spleen cells (e.g., splenocytes, splenic endothelial cells and splenic fibroblasts).</p><p id="p-0086" num="0082">In vivo delivery of the AAV virus or viral particle can be, for example, by injection, infusion, instillation, inhalation, or ingestion. &#x201c;Injection&#x201d; includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, intrasternal injection and infusion. The AAV virus or viral particle can be administered as a single bolus or multiple boluses, as a continuous infusion, or a combination thereof. In some embodiments, the AAV virus or viral particle can be administered into the blood stream of the subject.</p><p id="p-0087" num="0083">The dose of AAV virions or viral particles required to achieve a particular &#x201c;therapeutic effect,&#x201d; e.g., the units of dose in vector genomes/per kilogram of body weight (vg/kg), will vary based on several factors including, but not limited to: the route of AAV virus or viral particle administration, the level of gene expression required to achieve a therapeutic effect, the specific disease or disorder being treated, a host immune response to the AAV virus or viral particle, a host immune response to the gene expression product, and the stability of the gene product. One of skill in the art can readily determine a AAV virus or viral particle dose range to treat a patient having a particular disease or disorder based on the aforementioned factors, as well as other factors that are well known in the art. Generally speaking, by &#x201c;therapeutic effect&#x201d; is meant a level of expression of one or more transgenes in the AAV virus or viral particle sufficient to alter a component of a disease (or disorder) toward a desired outcome or clinical endpoint, such that a patient's disease or disorder shows clinical improvement, often reflected by the amelioration of a clinical sign or symptom relating to the disease or disorder. Exemplary doses for achieving therapeutic effects are AAV virus or viral particle titers of at least about 10<sup>5</sup>, 10<sup>6</sup>, 10<sup>7</sup>, 10<sup>8</sup>, 10<sup>9</sup>, 10<sup>10</sup>, 10<sup>11</sup>, 10<sup>12</sup>, 10<sup>13</sup>, 10<sup>14</sup>, 10<sup>15</sup>, 10<sup>16 </sup>transducing units or more. For example, from about 10<sup>8 </sup>to about 10<sup>13 </sup>transducing units. It is noted that more than one administration (e.g., two, three, four, or more administrations) can be employed to achieve desired (e.g. therapeutic) levels of gene expression.</p><heading id="h-0012" level="2">Levenshtein Distance</heading><p id="p-0088" num="0084">The Levenshtein distance has been calculated for the variant capsid polypeptides described herein. As used herein, the &#x201c;Levenshtein distance&#x201d; refers to a string metric for measuring the difference between two sequences. For example, the Levenshtein distance between two sequences is the minimum number of single-base pair edits (i.e. insertions, deletions, or substitutions) required to change one sequence into the other. In one embodiment, the variant capsid polypeptide has a Levenshtein distance of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 or more as compared to SEQ ID NO: 2 (wild-type VP1). The Levenshtein distance can be calculated by one skilled in the art, e.g., using the formula herein below the Levenshtein distance between two strings a, b (of length |a| and |b| respectively) is given by leva,b(|a|,|b|) where:</p><p id="p-0089" num="0000"><maths id="MATH-US-00001" num="00001"><math overflow="scroll"> <mrow>  <mrow>   <msub>    <mi>lev</mi>    <mrow>     <mi>a</mi>     <mo>,</mo>     <mi>b</mi>    </mrow>   </msub>   <mo>(</mo>   <mrow>    <mi>i</mi>    <mo>,</mo>    <mi>j</mi>   </mrow>   <mo>)</mo>  </mrow>  <mo>=</mo>  <mrow>   <mo>{</mo>   <mtable>    <mtr>     <mtd>      <mrow>       <mi>max</mi>       <mo>&#x2061;</mo>       <mo>(</mo>       <mrow>        <mi>i</mi>        <mo>,</mo>        <mi>j</mi>       </mrow>       <mo>)</mo>      </mrow>     </mtd>     <mtd>      <mrow>       <mrow>        <mrow>         <mi>if</mi>         <mo>&#x2062;</mo>         <mtext>   </mtext>         <mrow>          <mi>min</mi>          <mo>&#x2061;</mo>          <mo>(</mo>          <mrow>           <mi>i</mi>           <mo>,</mo>           <mi>j</mi>          </mrow>          <mo>)</mo>         </mrow>        </mrow>        <mo>=</mo>        <mn>0</mn>       </mrow>       <mo>,</mo>      </mrow>     </mtd>    </mtr>    <mtr>     <mtd>      <mrow>       <mi>min</mi>       <mo>&#x2062;</mo>       <mrow>        <mo>{</mo>        <mtable>         <mtr>          <mtd>           <mrow>            <mrow>             <msub>              <mi>lev</mi>              <mrow>               <mi>a</mi>               <mo>,</mo>               <mi>b</mi>              </mrow>             </msub>             <mo>(</mo>             <mrow>              <mrow>               <mi>i</mi>               <mo>-</mo>               <mn>1</mn>              </mrow>              <mo>,</mo>              <mi>j</mi>             </mrow>             <mo>)</mo>            </mrow>            <mo>+</mo>            <mn>1</mn>           </mrow>          </mtd>         </mtr>         <mtr>          <mtd>           <mrow>            <mrow>             <msub>              <mi>lev</mi>              <mrow>               <mi>a</mi>               <mo>,</mo>               <mi>b</mi>              </mrow>             </msub>             <mo>(</mo>             <mrow>              <mi>i</mi>              <mo>,</mo>              <mrow>               <mi>j</mi>               <mo>-</mo>               <mn>1</mn>              </mrow>             </mrow>             <mo>)</mo>            </mrow>            <mo>+</mo>            <mn>1</mn>           </mrow>          </mtd>         </mtr>         <mtr>          <mtd>           <mrow>            <mrow>             <msub>              <mi>lev</mi>              <mrow>               <mi>a</mi>               <mo>,</mo>               <mi>b</mi>              </mrow>             </msub>             <mo>(</mo>             <mrow>              <mrow>               <mi>i</mi>               <mo>-</mo>               <mn>1</mn>              </mrow>              <mo>,</mo>              <mrow>               <mi>j</mi>               <mo>-</mo>               <mn>1</mn>              </mrow>             </mrow>             <mo>)</mo>            </mrow>            <mo>+</mo>            <msub>             <mn>1</mn>             <mrow>              <mo>(</mo>              <mrow>               <msub>                <mi>a</mi>                <mi>i</mi>               </msub>               <mo>&#x2260;</mo>               <msub>                <mi>b</mi>                <mi>j</mi>               </msub>              </mrow>              <mo>)</mo>             </mrow>            </msub>           </mrow>          </mtd>         </mtr>        </mtable>       </mrow>      </mrow>     </mtd>     <mtd>      <mrow>       <mi>otherwise</mi>       <mo>.</mo>      </mrow>     </mtd>    </mtr>   </mtable>  </mrow> </mrow></math></maths></p><p id="p-0090" num="0000">where 1(ai&#x2260;bi) is the indicator function equal to 0 when ai&#x2260;bi and equal to 1 otherwise, and leva, b(i,j) is the distance between the first i characters of a and the first j characters of b.</p><p id="p-0091" num="0085">Note that the first element in the minimum corresponds to deletion (from a to b), the second to insertion and the third to match or mismatch, depending on whether the respective symbols are the same.</p><p id="p-0092" num="0086">Table 2 denotes the SEQ ID NOs that correspond to a particular Levenshtein distance to the wild-type (e.g., SEQ ID NO: 2). The SEQ IN NOs boundaries are inclusive (e.g. start_SEQ ID NO: 10, and end_SEQ ID NO: 15, means both SEQ ID NO: 10 and SEQ ID NO: 15 are included in the range).</p><p id="p-0093" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Levenshtein distance of sequences to the wild-type (SEQ ID NO: 2)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="91pt" align="center"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="63pt" align="center"/><tbody valign="top"><row><entry>Distance from Wild-type</entry><entry>Start SEQ ID NO</entry><entry>End SEQ ID NO</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="91pt" align="char" char="."/><colspec colname="2" colwidth="63pt" align="char" char="."/><colspec colname="3" colwidth="63pt" align="char" char="."/><tbody valign="top"><row><entry>0</entry><entry>2</entry><entry>3</entry></row><row><entry>2</entry><entry>4</entry><entry>5946</entry></row><row><entry>3</entry><entry>5947</entry><entry>14914</entry></row><row><entry>4</entry><entry>14915</entry><entry>23541</entry></row><row><entry>5</entry><entry>23542</entry><entry>30508</entry></row><row><entry>6</entry><entry>30509</entry><entry>36121</entry></row><row><entry>7</entry><entry>36122</entry><entry>37072</entry></row><row><entry>8</entry><entry>37073</entry><entry>37874</entry></row><row><entry>9</entry><entry>37875</entry><entry>38557</entry></row><row><entry>10</entry><entry>38558</entry><entry>39153</entry></row><row><entry>11</entry><entry>39154</entry><entry>39632</entry></row><row><entry>12</entry><entry>39633</entry><entry>39955</entry></row><row><entry>13</entry><entry>39956</entry><entry>40167</entry></row><row><entry>14</entry><entry>40168</entry><entry>40326</entry></row><row><entry>15</entry><entry>40327</entry><entry>40444</entry></row><row><entry>16</entry><entry>40445</entry><entry>40521</entry></row><row><entry>17</entry><entry>40522</entry><entry>40597</entry></row><row><entry>18</entry><entry>40598</entry><entry>40675</entry></row><row><entry>19</entry><entry>40676</entry><entry>40766</entry></row><row><entry>20</entry><entry>40767</entry><entry>40880</entry></row><row><entry>21</entry><entry>40881</entry><entry>41009</entry></row><row><entry>22</entry><entry>41010</entry><entry>41157</entry></row><row><entry>23</entry><entry>41158</entry><entry>41251</entry></row><row><entry>24</entry><entry>41252</entry><entry>41310</entry></row><row><entry>25</entry><entry>41311</entry><entry>41327</entry></row><row><entry>26</entry><entry>41328</entry><entry>41331</entry></row><row><entry>28</entry><entry>41332</entry><entry>41333</entry></row><row><entry>30</entry><entry>41334</entry><entry>41334</entry></row><row><entry>32</entry><entry>41335</entry><entry>41335</entry></row><row><entry>35</entry><entry>41336</entry><entry>41336</entry></row><row><entry>36</entry><entry>41337</entry><entry>41337</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0094" num="0087">Some exemplary embodiments of the invention can be described by the following numbered embodiments:</p><p id="p-0095" num="0088">Embodiment 1: A viral capsid polypeptide bearing a mutation relative to SEQ ID NO: 2 (WT AAV2) in a region corresponding to amino acids 561-588.</p><p id="p-0096" num="0089">Embodiment 2: The viral capsid polypeptide of Embodiment 1, wherein the region corresponding to amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0097" num="0090">Embodiment 3: The viral capsid polypeptide of Embodiments 1 or 2, which is an AAV capsid polypeptide.</p><p id="p-0098" num="0091">Embodiment 4: The viral capsid polypeptide of any of Embodiments 1-3, which is an AAV2 capsid polypeptide.</p><p id="p-0099" num="0092">Embodiment 5: An AAV VP1 capsid polypeptide bearing a mutation in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.</p><p id="p-0100" num="0093">Embodiment 6: The AAV VP1 capsid polypeptide of Embodiment 5, wherein the region corresponding to amino acids 561-588 of SEQ ID NO: 2 comprises a sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0101" num="0094">Embodiment 7: The AAV VP1 capsid polypeptide of Embodiments 5 or 6, which is an AAV2 capsid polypeptide.</p><p id="p-0102" num="0095">Embodiment 8: A viral capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0103" num="0096">Embodiment 9: A variant viral capsid polypeptide of SEQ ID 2, wherein the region of amino acids 561-588 comprises a sequence of SEQ ID NO: 4-41,337.</p><p id="p-0104" num="0097">Embodiment 10: An AAV2 capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.</p><p id="p-0105" num="0098">Embodiment 11: An engineered AAV vector having at least one capsid polypeptide comprising any one of the capsid polypeptides of Embodiments 1-10.</p><p id="p-0106" num="0099">Embodiment 12: A nucleic acid encoding the capsid polypeptide of any one of Embodiments 1-10.</p><p id="p-0107" num="0100">Embodiment 13: A viral particle comprising a capsid polypeptide of any one of Embodiments 1-10.</p><p id="p-0108" num="0101">Embodiment 14: A method for delivering a payload, the method comprising contacting a cell with any of the engineered AAV vectors of Embodiment 12, or viral particles of Embodiment 13.</p><p id="p-0109" num="0102">Embodiment 15: The method of Embodiment 14, wherein the contacting is sufficient to allow for expression of the payload in the cell.</p><p id="p-0110" num="0103">Embodiment 16: A method for administering a payload, the method comprising administering to a subject any of the engineered AAV vectors of Embodiment 12, or viral particles of Embodiment 13.</p><p id="p-0111" num="0104">Embodiment 17: The method of Embodiment 16, wherein the administering is sufficient to allow for expression of the payload in the cell.</p><p id="p-0112" num="0105">Embodiment 18: The method of any of Embodiments 14-17, wherein the payload is selected from the group consisting of: a nucleic acid, a polypeptide, an inhibitory RNA, an antibody or antibody reagent, an oligonucleotide, and a miRNA.</p><heading id="h-0013" level="1">Definitions</heading><p id="p-0113" num="0106">For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims, are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed technology, because the scope of the technology is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.</p><p id="p-0114" num="0107">Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th Edition, published by Merck Sharp &#x26; Dohme Corp., 2011 (ISBN 978-0-911910-19-3); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor &#x26; Francis Limited, 2014 (ISBN 0815345305, 9780815345305); Lewin's Genes XI, published by Jones &#x26; Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated by reference herein in their entireties. As used herein, the term &#x201c;comprising&#x201d; means that other elements can also be present in addition to the defined elements presented. The use of &#x201c;comprising&#x201d; indicates inclusion rather than limitation.</p><p id="p-0115" num="0108">The term &#x201c;consisting of&#x201d; refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.</p><p id="p-0116" num="0109">As used herein the term &#x201c;consisting essentially of&#x201d; refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the technology.</p><p id="p-0117" num="0110">The word &#x201c;or&#x201d; is intended to include &#x201c;and&#x201d; unless the context clearly indicates otherwise.</p><p id="p-0118" num="0111">In some embodiments, the terms &#x201c;a&#x201d; and &#x201c;an&#x201d; and &#x201c;the&#x201d; and similar references used in the context of describing a particular embodiment of the invention (especially in the context of certain of the following claims) can be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. &#x201c;such as&#x201d;) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.</p><p id="p-0119" num="0112">The abbreviation, &#x201c;e.g.&#x201d; is derived from the Latin Exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation &#x201c;e.g.&#x201d; is synonymous with the term &#x201c;for example.&#x201d;</p><p id="p-0120" num="0113">As used herein, the term &#x201c;viral capsid polypeptide&#x201d; refers to the proteinaceous shell or coat of a viral particle. At a minimum, a viral capsid polypeptide as described herein permits packaging or assembly of the capsid polypeptide into a viral particle that is competent for delivery of nucleic acid to the host cell. Capsids function to encapsidate, protect, transport, and release into a host cell a viral genome. Capsids are generally comprised of oligomeric structural subunits of a polypeptide of the viral capsid polypeptides. As used herein, the term &#x201c;encapsidated&#x201d; means enclosed within a viral capsid. As an example, the AAV genome comprises three overlapping sequences which encode capsid proteins, VP1, VP2 and VP3, which start from one promoter, p40. The AAV capsid is composed of a mixture of VP1, VP2, and VP3 totaling 60 monomers arranged in icosahedral symmetry in a ratio of 1:1:10.</p><p id="p-0121" num="0114">As used herein, &#x201c;packaging&#x201d; refers to a series of intracellular events that result in the assembly and encapsidation of an AAV particle.</p><p id="p-0122" num="0115">As used herein, &#x201c;payload&#x201d; refers to a nucleic acid which is encapsidated within a viral vector, e.g., an AAV vector. A payload nucleic acid can encode, e.g., a polypeptide, an inhibitory RNA, an antibody or antibody reagent, an oligonucleotide, or a miRNA.</p><p id="p-0123" num="0116">The term &#x201c;polypeptide&#x201d; as used herein refers to a polymer of amino acids. The terms &#x201c;protein&#x201d; and &#x201c;polypeptide&#x201d; are used interchangeably herein. A peptide is a relatively short polypeptide, typically between about 2 and 60 amino acids in length. Polypeptides used herein typically contain amino acids such as the 20 L-amino acids that are most commonly found in proteins. However, other amino acids and/or amino acid analogs known in the art can be used. One or more of the amino acids in a polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a fatty acid group, a linker for conjugation, functionalization, etc. A polypeptide that has a nonpolypeptide moiety covalently or noncovalently associated therewith is still considered a &#x201c;polypeptide.&#x201d; Exemplary modifications include glycosylation and palmitoylation. Polypeptides can be purified from natural sources, produced using recombinant DNA technology or synthesized through chemical means such as conventional solid phase peptide synthesis, etc. The term &#x201c;polypeptide sequence&#x201d; or &#x201c;amino acid sequence&#x201d; as used herein can refer to the polypeptide material itself and/or to the sequence information (i.e., the succession of letters or three letter codes used as abbreviations for amino acid names) that biochemically characterizes a polypeptide. A polypeptide sequence presented herein is presented in an N-terminal to C-terminal direction unless otherwise indicated.</p><p id="p-0124" num="0117">A given amino acid can be replaced by a residue having similar physicochemical characteristics, e.g., substituting one aliphatic residue for another (such as Ile, Val, Leu, or Ala for one another), or substitution of one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gln and Asn). Other such conservative substitutions, e.g., substitutions of entire regions having similar hydrophobicity characteristics, are well known. Polypeptides comprising conservative amino acid substitutions can be tested in any one of the assays described herein to confirm that a desired activity, e.g. ligand-mediated receptor activity and specificity of a native or reference polypeptide is retained.</p><p id="p-0125" num="0118">Amino acids can be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Particular conservative substitutions include, for example; Ala into Gly or into Ser; Arg into Lys; Asn into Gln or into His; Asp into Glu; Cys into Ser; Gln into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gln; Ile into Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gln or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr; Tyr into Trp; and/or Phe into Val, into Ile or into Leu.</p><p id="p-0126" num="0119">In some embodiments, a polypeptide described herein (or a nucleic acid encoding such a polypeptide) can be a functional fragment of one of the amino acid sequences described herein. As used herein, a &#x201c;functional fragment&#x201d; is a fragment or segment of a peptide which retains at least 50% of the wild-type reference polypeptide's activity according to an assay known in the art or described below herein. For example, a functional fragment described herein would retain at least 50% of the VP1 capsid function. One skilled in the art can assess the function of VP1 using standard techniques, for example those described herein below. A functional fragment can comprise conservative substitutions of the sequences disclosed herein.</p><p id="p-0127" num="0120">In some embodiments, a polypeptide described herein can be a variant of a polypeptide or molecule as described herein. In some embodiments, the variant is a conservatively modified variant. Conservative substitution variants can be obtained by mutations of native nucleotide sequences, for example. A &#x201c;variant,&#x201d; as referred to herein, is a polypeptide substantially homologous to a native or reference polypeptide, e.g., SEQ ID NO: 2, but which has an amino acid sequence different from that of the native or reference polypeptide because of one or a plurality of deletions, insertions or substitutions. A variant capsid polypeptide as the term is used herein retains the capacity for assembly into a viral capsid. Variant polypeptide-encoding DNA sequences encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to a native or reference DNA sequence, e.g., SEQ ID NO: 1, but that encode a variant protein or fragment thereof that retains activity of the non-variant polypeptide. A wide variety of PCR-based site-specific mutagenesis approaches are known in the art and can be applied by the ordinarily skilled artisan.</p><p id="p-0128" num="0121">A variant amino acid or DNA sequence can be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to a native or reference sequence. The degree of homology (percent identity) between a native and a mutant sequence can be determined, for example, by comparing the two sequences using computer programs commonly employed for this purpose, e.g., that are freely available on the world wide web (e.g. BLASTp or BLASTn with default settings). Alterations of the native amino acid sequence can be accomplished by any of a number of techniques known to one of skill in the art. Mutations can be introduced, for example, at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites permitting ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes an analog having the desired amino acid insertion, substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered nucleotide sequence having particular codons altered according to the substitution, deletion, or insertion required. Techniques for making such alterations are well established and include, for example, those disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Pat. Nos. 4,518,584 and 4,737,462, which are herein incorporated by reference in their entireties. Any cysteine residue not involved in maintaining the proper conformation of a polypeptide also can be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) can be added to a polypeptide to improve its stability or facilitate oligomerization.</p><p id="p-0129" num="0122">As used herein, the term &#x201c;DNA&#x201d; is defined as deoxyribonucleic acid. The term &#x201c;polynucleotide&#x201d; is used herein interchangeably with &#x201c;nucleic acid&#x201d; to indicate a polymer of nucleosides. Typically, a polynucleotide is composed of nucleosides that are naturally found in DNA or RNA (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) joined by phosphodiester bonds. However, the term encompasses molecules comprising nucleosides or nucleoside analogs containing chemically or biologically modified bases, modified backbones, etc., whether or not found in naturally occurring nucleic acids, and such molecules may be preferred for certain applications. Where this specification refers to a polynucleotide it is understood that both DNA, RNA, and in each case both single- and double-stranded forms (and complements of each single-stranded molecule) are provided. &#x201c;Polynucleotide sequence&#x201d; as used herein can refer to the polynucleotide material itself and/or to the sequence information (i.e. the succession of letters used as abbreviations for bases) that biochemically characterizes a specific nucleic acid. A polynucleotide sequence presented herein is presented in a 5&#x2032; to 3&#x2032; direction unless otherwise indicated.</p><p id="p-0130" num="0123">As used herein, the term &#x201c;viral vector&#x201d; refers to a nucleic acid vector construct that includes at least one element of viral origin and has the capacity to be packaged into a viral particle. The viral vector can contain a nucleic acid (e.g., a payload) encoding a polypeptide as described herein in place of non-essential viral genes. The vector and/or particle may be utilized for the purpose of transferring nucleic acids into cells either in vitro or in vivo. Numerous forms of viral vectors are known in the art.</p><p id="p-0131" num="0124">As used herein, an &#x201c;AAV virus&#x201d; or &#x201c;AAV viral particle&#x201d; refers to a viral particle composed of at least one AAV capsid protein such as VP1 (typically by all of the capsid proteins of a wild-type AAV) and an encapsidated polynucleotide rAAV vector. If the particle comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild-type AAV genome, such as a transgene to be delivered to a mammalian cell), it is typically referred to as a &#x201c;recombinant AAV vector particle&#x201d; or simply a &#x201c;rAAV vector&#x201d;. Thus, production of a rAAV particle necessarily includes production of a rAAV vector, as such a vector is contained within a rAAV particle.</p><p id="p-0132" num="0125">As used herein, the term &#x201c;corresponding to,&#x201d; when used in reference to an amino acid or polynucleotide sequence means that a given amino acid or polynucleotide sequence in one polypeptide or polynucleotide molecule has structural properties, functional properties, or both that are similar relative to an amino acid or polynucleotide sequence in a similar location in another polypeptide or polynucleotide molecule. Homologues of a given polypeptide in different species &#x201c;correspond to&#x201d; each other, as do regions or domains of homologous polypeptides from different species. Similarly, capsid polypeptides of different serotypes of viral vectors, including but not limited to adeno-associated virus (AAV) vectors, &#x201c;correspond to&#x201d; each other, as do regions of such polypeptides, defined, for example by alignment of their amino acid sequences. While other alignment parameters can be used to define such regions, for the avoidance of doubt, alignment can be performed using BLAST&#xae; (Basic Local Alignment Search Tool) using default parameters of version BLAST+ 2.8.0 released Mar. 28, 2018.</p><p id="p-0133" num="0126">As used herein, a &#x201c;transgene&#x201d; is a polynucleotide encoding a gene that is delivered to a cell by a vector.</p><p id="p-0134" num="0127">A &#x201c;gene&#x201d; refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular gene product after being transcribed, and sometimes also translated. The term &#x201c;gene&#x201d; or &#x201c;coding sequence&#x201d; refers to a nucleotide sequence in vitro or in vivo that encodes a gene product. In some instances, the gene consists or consists essentially of coding sequence, that is, sequence that encodes the gene product. In other instances, the gene comprises additional, non-coding, sequence that permits, facilitates or directs the cellular expression machinery to express the encoded product. Such sequences can include, but are not limited to promoters, enhancers, transcriptional termination and/or poly(A) addition signals, and elements that affect transcript processing and/or stability. A gene may or may not include regions preceding and following the coding region, e.g. 5&#x2032; untranslated (5&#x2032; UTR) or &#x201c;leader&#x201d; sequences and 3&#x2032; UTR or &#x201c;trailer&#x201d; sequences, as well as intervening sequences (introns) between individual coding segments (exons).</p><p id="p-0135" num="0128">A &#x201c;gene product&#x201d; is a molecule resulting from expression of a particular gene. Gene products include, e.g., a polypeptide, an aptamer, an interfering RNA, an mRNA, and the like. In particular embodiments, a &#x201c;gene product&#x201d; is a polypeptide, peptide, protein or interfering RNA including short interfering RNA (siRNA), miRNA or small hairpin RNA (shRNA). In particular embodiments, a gene product is a therapeutic gene product, e.g., a therapeutic protein, or a therapeutic RNA.</p><p id="p-0136" num="0129">As used herein, a &#x201c;therapeutic gene&#x201d; refers to a gene that, when expressed, produces a therapeutic gene product that confers a beneficial effect on the cell or tissue in which it is present, or on a mammal in which the gene is expressed. Examples of beneficial effects include amelioration of a sign or symptom of a condition or disease, prevention or inhibition of a condition or disease, or conferral of a desired characteristic. Therapeutic genes include, but are not limited to, genes that correct a genetic deficiency in a cell or mammal.</p><p id="p-0137" num="0130">All patents, patent applications, and publications identified are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-0"><p id="p-0138" num="00001"><tables id="MEGA-SEQ-0" num="0"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="center"/><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>SEQUENCE LISTING</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="441pt" align="left"/><tbody valign="top"><row><entry>The patent application contains a lengthy &#x201c;Sequence Listing&#x201d; section. A copy of the &#x201c;Sequence Listing&#x201d; is available in electronic form from the USPTO web site (<?PSIPSURL description="PSIPS url" end="lead"?><![CDATA[https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20230002451A1]]><?PSIPSURL description="PSIPS url" end="tail"?>). An electronic copy of the &#x201c;Sequence Listing&#x201d; will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).</entry></row></tbody></tgroup></table></tables></p><sequence-list file="//20230105-SUPP/US20230002451A1-20230105-SUPP.ZIP | US20230002451A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-math idrefs="MATH-US-00001" nb-file="US20230002451A1-20230105-M00001.NB"><img id="EMI-M00001" he="13.38mm" wi="76.20mm" file="US20230002451A1-20230105-M00001.TIF" alt="embedded image " img-content="math" img-format="tif"/></us-math><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A viral capsid polypeptide bearing a mutation relative to SEQ ID NO: 2 (WT AAV2) in a region corresponding to amino acids 561-588.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The viral capsid polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the region corresponding to amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The viral capsid polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, which is an AAV capsid polypeptide.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The viral capsid polypeptide of <claim-ref idref="CLM-00001">claim 1</claim-ref>, which is an AAV2 capsid polypeptide.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. An AAV VP1 capsid polypeptide bearing a mutation in the region corresponding to amino acids 561-588 of SEQ ID NO: 2.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The AAV VP1 capsid polypeptide of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the region corresponding to amino acids 561-588 of SEQ ID NO: 2 comprises a sequence selected from SEQ ID NO: 4-41,337.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The AAV VP1 capsid polypeptide of <claim-ref idref="CLM-00005">claim 5</claim-ref>, which is an AAV2 capsid polypeptide.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. A viral capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. A variant of the viral capsid polypeptide of SEQ ID NO: 2, wherein the region of amino acids 561-588 comprises a sequence selected from SEQ ID NO: 4-41,337.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. An AAV2 capsid polypeptide comprising a sequence of SEQ ID NO: 2, wherein the region of amino acids 561-588 of SEQ ID NO: 2 comprises a variant sequence selected from SEQ ID NO: 4-41,337.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. A nucleic acid encoding the capsid polypeptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. An engineered AAV vector having at least capsid polypeptide comprising any one of the capsid polypeptides of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. A viral particle comprising a capsid polypeptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A method for delivering a payload, the method comprising contacting a cell with any of the engineered AAV vectors of <claim-ref idref="CLM-00012">claim 12</claim-ref>, or viral particles of <claim-ref idref="CLM-00013">claim 13</claim-ref>.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method of <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the contacting is sufficient to allow for expression of the payload in the cell.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A method for administering a payload, the method comprising administering to a subject any of the engineered AAV vectors of <claim-ref idref="CLM-00012">claim 12</claim-ref>, or viral particles of <claim-ref idref="CLM-00013">claim 13</claim-ref>.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method of <claim-ref idref="CLM-00016">claim 16</claim-ref>, wherein the administering is sufficient to allow for expression of the payload in the cell.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method of any of <claim-ref idref="CLM-00014">claims 14</claim-ref>-<claim-ref idref="CLM-00017">17</claim-ref>, wherein the payload is selected from the group consisting of: a nucleic acid, a polypeptide, an inhibitory RNA, an antibody or antibody reagent, an oligonucleotide, and a miRNA.</claim-text></claim></claims></us-patent-application>